Two Utah sisters have each had their entire stomach removed as a preventive measure to spare painful, cancer-filled future ...

Some clinical trials for treatments that nip Alzheimer’s disease in the bud rely on recruiting carriers of autosomal-dominant mutations who will develop Alzheimer’s disease in a predictable fashion.

Germline mutations may be “dominant” or “recessive.” In autosomal dominant diseases, one parent has a normal copy of the gene and a mutated copy; there is a 50-50 chance a child will ...

Regulus Therapeutics will be acquired by Novartis AG for $7 per share in cash. Click here for more information on RGLS ...

The ongoing DIAN-TU platform tests the safety and effectiveness of investigational drugs in people at risk of developing Alzheimer's due to autosomal dominant mutations in PSEN1, PSEN2 ...

Huntington described the autosomal dominant inheritance pattern of this ... all affected individuals would carry the same original mutation as the founder. Over a period of more than 20 years ...

Autosomal dominant single-gene diseases occur in individuals ... to potentially "cancel out" the negative effects of X-linked mutations, they are far more likely than women to be affected by ...

At the heart of the acquisition is Regulus’ farabursen, an miRNA-targeting oligonucleotide in early-stage development for ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and ...

Researchers have developed a machine learning model that predicts Cas9 proteins that can be tailored with designer properties for therapeutic use.

Semaglutide promising alternative treatment for chronic myopathy of hyperkalemic periodic paralysis suggests a case report ...